ClinicalTrials.gg
TerminatedNCT01379521TRACERUpdated May 3, 2017Results posted

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC

A Phase 2 interventional study of everolimus and everolimus placebo in Hepatocellular Carcinoma, sponsored by Novartis Pharmaceuticals. Terminated at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated due to low enrollment. This resulted in the study being underpowered and inconclusive.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Carcinoma, Hepatocellular by Novartis — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Novartis.

Enrollment
6th of 10
65 · median 98
Started
2011
with 1 other
Phase 2
5 of 10
none open now
Registered
6th of 10
by date

Among the 10 studies in Carcinoma, Hepatocellular by Novartis, this one is the 6th largest by enrollment, is one of 2 that started in 2011, is one of 5 in phase 2, and was the 6th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 10 studies in Carcinoma, Hepatocellular by Novartis is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Carcinoma, Hepatocellular by Novartis as a file.
02

Study summary

This study will evaluate the role of everolimus in combination with local Transcatheter Arterial Chemoembolization (TACE) procedure in patients with localized unresectable Hepatocellular Carcinoma (HCC).

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Localised
  • unresectable
  • chemoembolization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed hepatocellular carcinoma limited to liver and not suitable for resection, liver transplant, or radiofrequency ablation.
  • Intermediate stage (stage B) (according to recognized guidelines) and suitable for TACE therapy
  • At least one nodule between > 2cm and ≤ 15cm in diameter with no vascular invasion or abdominal lymph node or distant .
  • Must have 1 tumor which can be measured in 1 dimension according to specified criteria ( and ) and has not previously been treated with any type of therapy.
  • performance status \< 2cm
  • Cirrhotic status of class A or early B
  • or HBsAg positive at screen or baseline: preventative treatment with anti-viral started 1-2 weeks prior to receiving study drug

Exclusion criteria

Exclusion Criteria:

  • Any local and/or drugs within 28 days prior to randomization
  • Active bleeding during the last 28 days prior to screening including variceal bleeding
  • Prior therapy with mTOR inhibitors
  • Tumor burden of > 60% liver involvement
  • Prior systemic or local therapy including TACE except for the first TACE at Day 0), surgery or liver transplantation
  • Failed first TACE at Day 0, Cycle 1 for any reason
  • Known history of (HIV) seropositivity (HIV testing is not mandatory)
  • Alcohol intake of 80 grams per day
  • Undergone major surgery ≤ 3 weeks prior to starting study drug or who have not recovered from surgery
  • Female patients who are pregnant or breast feeding, or adults of who are not using effective methods

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    everolimus + TACE

    everolimus 7.5mg/day by mouth + transcatheter arterial chemoembolization (TACE)

    Drug: everolimus

  • Placebo comparator
    placebo + TACE

    Placebo by mouth + transcatheter arterial chemoembolization (TACE)

    Drug: everolimus placebo

Interventions

  • Also known as: RAD001, Afinitor®)

  • Drugeverolimus placebo
06

What researchers measure

Primary outcomes

  1. Time to Progression (TTP) Based on the Modified RECIST Criteria

    Time to Progression (TTP) defined as the time from the date of randomization to the date of first documented radiological confirmation of disease progression based on modified RECIST criteria. Progressive Disease: \>20% increase in sum of the longest diameters (SLD) of "viable" target lesion (arterial phase enhancement)

    Time frame: 3, 6, 12, 18 and 24 months

Secondary outcomes

  1. Overall Response Rate (ORR) and Disease Control Rate (DCR) Based on the Modified RECIST

    Overall response rate was defined as the number of patients whose best overall response was either complete response or partial response according to the modified RECIST. Complete response: Disappearance of arterial phase enhance-ment in all target lesions. Partial response: \>30% decrease in sum of the longest diameters (SLD) of "viable" target lesion (arterial phase enhance-ment)Disease control rate was defined as the number of patients with a best overall response of complete response, partial response or stable disease. The study was terminated early due to slow enrollment of 4 years, higher than anticipated screen failure rate due to a higher than anticipated proportion of patients having advanced liver disease and a change in clinical practice the total of 80 patients was not reached with only 59 patients recruited in total. The study was underpowered due to termination therefore data was not collected and the outcome measure was not analyzed.

    Time frame: 6, 12 months, end of study

  2. Time to Progression Based on Original RECIST

    Time to Progression (TTP) defined as the time from the date of randomization to the date of first documented radiological confirmation of disease progression based on original RECIST criteria. Progressive Disease: \>20% increase in sum of the longest diameters (SLD) of target lesions with an absolute increase of ≥5 mm; new lesions. The study was terminated early due to slow enrollment of 4 years, higher than anticipated screen failure rate due to a higher than anticipated proportion of patients having advanced liver disease and a change in clinical practice the total of 80 patients was not reached with only 59 patients recruited in total. The study was underpowered due to termination therefore data was not collected and the outcome measure was not analyzed.

    Time frame: 6, 12 months, end of study

  3. Overall Response Rate (ORR) and Disease Control Rate (DCR) Based on Original RECIST

    Overall response rate was defined as the number of patients whose best overall response was either complete response or partial response according to the Complete response: Disappearance of all target lesions or lymph nodes \<10 mm in the short axis Partial response: \>30% decrease in sum of the longest diameters (SLD) of target lesions Disease control rate was defined as the number of patients with a best overall response of complete response, partial response or stable disease. The study was terminated early due to slow enrollment of 4 years, higher than anticipated screen failure rate due to a higher than anticipated proportion of patients having advanced liver disease and a change in clinical practice the total of 80 patients was not reached with only 59 patients recruited in total. The study was underpowered due to termination therefore data was not collected and the outcome measure was not analyzed.

    Time frame: 6, 12 months, end of study

  4. Overall Survival (OS)

    Overall survival was defined as the time from date of randomization to date of death due to any cause. If death had not occurred at the date of the analysis cut-off then OS was censored at the date of the last contact.

    Time frame: 6, 12, 18, 24, 30 months

  5. Incidences of Cumulative New Nodular Recurrence, Portal Vein Invasion and Extra Hepatic Metastases

    Incidences of cumulative new nodular recurrence, portal vein invasion and extra hepatic metastases but incidence of portal vein invasion meant those patients without documented vascular invasion at screening/baseline. The study was terminated early due to slow enrollment of 4 years, higher than anticipated screen failure rate due to a higher than anticipated proportion of patients having advanced liver disease and a change in clinical practice the total of 80 patients was not reached with only 59 patients recruited in total. The study was underpowered due to termination therefore data was not collected and the outcome measure was not analyzed.

    Time frame: 30 months

  6. Percentage of Participants With a Decrease in the Sum of the of Longest Diameters (SLD) of Target Lesions From Baseline to 30 Months

    Percentage of participants with a decrease in the sum of the of longest diameters (SLD) of target lesions from Baseline to 30 months

    Time frame: baseline, 30 months

07

Results

Posted May 3, 2017

Participant flow

Of the 65 patients who were screened they reflect the actual enrolment but 59 patients were randomized and were included in the FAS, the Safety Set and the PP Set. There were no exclusions. Post-Treatment evaluations included any patients that was treated and does not reflect the number completed in the Overall Study.

Overall Study -Treatment Period
Participant flow — Overall Study -Treatment Period
MilestoneEverolimus + TACEPlacebo + TACE
Started3326
Completed00
Not completed3326
Withdrew: Adverse event30
Withdrew: Abnormal test procedure results01
Withdrew: Disease progression2322
Withdrew: New cancer therapy10
Withdrew: Protocol deviation02
Withdrew: Withdrawal by subject30
Withdrew: Administrative problems10
Withdrew: Death21
Post-Treatment Evaluations
Participant flow — Post-Treatment Evaluations
MilestoneEverolimus + TACEPlacebo + TACE
Started2521
Completed00
Not completed2521
Withdrew: Disease progression2220
Withdrew: Withdrawal by subject21
Withdrew: Death10

Outcome measures

PrimaryTime to Progression (TTP) Based on the Modified RECIST Criteria

Time to Progression (TTP) defined as the time from the date of randomization to the date of first documented radiological confirmation of disease progression based on modified RECIST criteria. Progressive Disease: \>20% increase in sum of the longest diameters (SLD) of "viable" target lesion (arterial phase enhancement)

Time frame:
3, 6, 12, 18 and 24 months
Reported as:
Median · months
Time to Progression (TTP) Based on the Modified RECIST Criteria
monthsEverolimus + TACEPlacebo + TACE
Time to Progression (TTP) Based on the Modified RECIST Criteria6.3 (4.3 to 6.6)6.4 (4.0 to 8.9)
SecondaryOverall Response Rate (ORR) and Disease Control Rate (DCR) Based on the Modified RECIST

Overall response rate was defined as the number of patients whose best overall response was either complete response or partial response according to the modified RECIST. Complete response: Disappearance of arterial phase enhance-ment in all target lesions. Partial response: \>30% decrease in sum of the longest diameters (SLD) of "viable" target lesion (arterial phase enhance-ment)Disease control rate was defined as the number of patients with a best overall response of complete response, partial response or stable disease. The study was terminated early due to slow enrollment of 4 years, higher than anticipated screen failure rate due to a higher than anticipated proportion of patients having advanced liver disease and a change in clinical practice the total of 80 patients was not reached with only 59 patients recruited in total. The study was underpowered due to termination therefore data was not collected and the outcome measure was not analyzed.

Time frame:
6, 12 months, end of study

No measurements were reported for this outcome.

SecondaryTime to Progression Based on Original RECIST

Time to Progression (TTP) defined as the time from the date of randomization to the date of first documented radiological confirmation of disease progression based on original RECIST criteria. Progressive Disease: \>20% increase in sum of the longest diameters (SLD) of target lesions with an absolute increase of ≥5 mm; new lesions. The study was terminated early due to slow enrollment of 4 years, higher than anticipated screen failure rate due to a higher than anticipated proportion of patients having advanced liver disease and a change in clinical practice the total of 80 patients was not reached with only 59 patients recruited in total. The study was underpowered due to termination therefore data was not collected and the outcome measure was not analyzed.

Time frame:
6, 12 months, end of study

No measurements were reported for this outcome.

SecondaryOverall Response Rate (ORR) and Disease Control Rate (DCR) Based on Original RECIST

Overall response rate was defined as the number of patients whose best overall response was either complete response or partial response according to the Complete response: Disappearance of all target lesions or lymph nodes \<10 mm in the short axis Partial response: \>30% decrease in sum of the longest diameters (SLD) of target lesions Disease control rate was defined as the number of patients with a best overall response of complete response, partial response or stable disease. The study was terminated early due to slow enrollment of 4 years, higher than anticipated screen failure rate due to a higher than anticipated proportion of patients having advanced liver disease and a change in clinical practice the total of 80 patients was not reached with only 59 patients recruited in total. The study was underpowered due to termination therefore data was not collected and the outcome measure was not analyzed.

Time frame:
6, 12 months, end of study

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Overall survival was defined as the time from date of randomization to date of death due to any cause. If death had not occurred at the date of the analysis cut-off then OS was censored at the date of the last contact.

Time frame:
6, 12, 18, 24, 30 months
Reported as:
Median · months
Overall Survival (OS)
monthsEverolimus + TACEPlacebo + TACE
Overall Survival (OS)29.9 (12.0 to NA)21.7 (19.4 to 27.9)
SecondaryIncidences of Cumulative New Nodular Recurrence, Portal Vein Invasion and Extra Hepatic Metastases

Incidences of cumulative new nodular recurrence, portal vein invasion and extra hepatic metastases but incidence of portal vein invasion meant those patients without documented vascular invasion at screening/baseline. The study was terminated early due to slow enrollment of 4 years, higher than anticipated screen failure rate due to a higher than anticipated proportion of patients having advanced liver disease and a change in clinical practice the total of 80 patients was not reached with only 59 patients recruited in total. The study was underpowered due to termination therefore data was not collected and the outcome measure was not analyzed.

Time frame:
30 months

No measurements were reported for this outcome.

SecondaryPercentage of Participants With a Decrease in the Sum of the of Longest Diameters (SLD) of Target Lesions From Baseline to 30 Months

Percentage of participants with a decrease in the sum of the of longest diameters (SLD) of target lesions from Baseline to 30 months

Time frame:
baseline, 30 months
Reported as:
Number · Percentage of participants
Percentage of Participants With a Decrease in the Sum of the of Longest Diameters (SLD) of Target Lesions From Baseline to 30 Months
Percentage of participantsEverolimus + TACEPlacebo + TACE
Percentage of Participants With a Decrease in the Sum of the of Longest Diameters (SLD) of Target Lesions From Baseline to 30 Months93.888.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus + TACE—10/33 (30.3%)33/33 (100%)
Placebo + TACE—7/26 (26.9%)25/26 (96.2%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventEverolimus + TACEPlacebo + TACE
PyrexiaGeneral disorders2/330/26
Abdominal painGastrointestinal disorders0/331/26
Intestinal ischaemiaGastrointestinal disorders0/331/26
Liver abscessInfections and infestations1/331/26
Peritonitis bacterialInfections and infestations0/331/26
PneumoniaInfections and infestations1/331/26
SepsisInfections and infestations0/331/26
HypotensionVascular disorders0/331/26
Hypovolaemic shockVascular disorders0/331/26
Acute myocardial infarctionCardiac disorders1/330/26
Most frequent other events
Showing 10 of 50
Most frequent other events
EventEverolimus + TACEPlacebo + TACE
Abdominal painGastrointestinal disorders19/3317/26
PyrexiaGeneral disorders12/3312/26
Decreased appetiteMetabolism and nutrition disorders11/335/26
ConstipationGastrointestinal disorders6/338/26
Mouth ulcerationGastrointestinal disorders9/332/26
Abdominal pain upperGastrointestinal disorders8/335/26
VomitingGastrointestinal disorders7/336/26
CoughRespiratory, thoracic and mediastinal disorders6/336/26
StomatitisGastrointestinal disorders7/330/26
InsomniaPsychiatric disorders7/335/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Everolimus + TACEPlacebo + TACETotal
Mean58.5 ± 11.2961.0 ± 10.3259.6 ± 10.85
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus + TACEPlacebo + TACETotal
Female4711
Male291948
08

Study locations

5 sites
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Kaohsiung, 807, Taiwan
  • Novartis Investigative Site
    Kaohsiung, 83301, Taiwan
  • Novartis Investigative Site
    Lin-Kou, 33305, Taiwan
  • Novartis Investigative Site
    Chiang Mai, 50200, Thailand
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2011
First posted
Jun 23, 2011
Start
Jun 2011
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
May 3, 2017
Last update
May 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01379521
Responsible party
Sponsor
First posted
Jun 23, 2011
Start date
Jun 2011
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
May 3, 2017
Last update
May 3, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion